非小细胞肺癌脑转移靶向治疗及免疫治疗进展

Progress of targeted therapy and immunotherapy for brain metastasis of nonsmall cell lung cancer

非小细胞肺癌(NSCLC)患者常见脑转移,发病率为25%~40%,预后极差且常伴有严重神经功能障碍,未经治疗平均中位生存期仅为1~2个月。靶向治疗和免疫治疗为NSCLC脑转移患者治疗开辟了新的途径,改善脑转移后神经功能障碍,延长中位生存期。本文就NSCLC脑转移靶向治疗及免疫治疗进展进行综述。

Brain metastases are common in patients with non-small cell lung cancer(NSCLC),with an incidence of 25%~40%. Patients with brain metastases possesses poor prognosis associated with severe neurological dysfunction,which exhibit only1~2 months of mean median survival without treatment. Targeted therapy and immunotherapy have opened up a new way for the treatment of patients with NSCLC brain metastasis,which can improve neurological dysfunction after brain metastasis and prolong median survival time. This article reviews progress of targeted therapy and immunotherapy for NSCLC with brain metastasis.